ATE89165T1 - Verwendung von thromboxan-a2-antagonisten zur herstellung eines arzneimittels zur wiederherstellung von post-ischaemischer myokard- dysfunktion. - Google Patents

Verwendung von thromboxan-a2-antagonisten zur herstellung eines arzneimittels zur wiederherstellung von post-ischaemischer myokard- dysfunktion.

Info

Publication number
ATE89165T1
ATE89165T1 AT88114866T AT88114866T ATE89165T1 AT E89165 T1 ATE89165 T1 AT E89165T1 AT 88114866 T AT88114866 T AT 88114866T AT 88114866 T AT88114866 T AT 88114866T AT E89165 T1 ATE89165 T1 AT E89165T1
Authority
AT
Austria
Prior art keywords
post
thromboxan
medication
antagonists
restoration
Prior art date
Application number
AT88114866T
Other languages
English (en)
Inventor
Gary James Grover
Irvin Edgar Fulmor Iii
Original Assignee
Squibb & Sons Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb & Sons Inc filed Critical Squibb & Sons Inc
Application granted granted Critical
Publication of ATE89165T1 publication Critical patent/ATE89165T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT88114866T 1987-09-17 1988-09-12 Verwendung von thromboxan-a2-antagonisten zur herstellung eines arzneimittels zur wiederherstellung von post-ischaemischer myokard- dysfunktion. ATE89165T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/098,424 US4931460A (en) 1987-09-17 1987-09-17 Post-ischemic myocardial dysfunction using thromboxane A2 antagonists
EP88114866A EP0309801B1 (de) 1987-09-17 1988-09-12 Verwendung von Thromboxan-A2-Antagonisten zur Herstellung eines Arzneimittels zur Wiederherstellung von post-ischämischer Myokard-Dysfunktion

Publications (1)

Publication Number Publication Date
ATE89165T1 true ATE89165T1 (de) 1993-05-15

Family

ID=22269223

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88114866T ATE89165T1 (de) 1987-09-17 1988-09-12 Verwendung von thromboxan-a2-antagonisten zur herstellung eines arzneimittels zur wiederherstellung von post-ischaemischer myokard- dysfunktion.

Country Status (6)

Country Link
US (1) US4931460A (de)
EP (1) EP0309801B1 (de)
JP (1) JPH0283319A (de)
AT (1) ATE89165T1 (de)
CA (1) CA1328607C (de)
DE (1) DE3880943T2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231084A (en) * 1986-03-27 1993-07-27 Hoechst Aktiengesellschaft Compounds having a cognition adjuvant action, agents containing them, and the use thereof for the treatment and prophylaxis of cognitive dysfuncitons
DE4010536A1 (de) * 1990-04-02 1991-10-10 Boehringer Mannheim Gmbh Pharmazeutische waessrige loesung von 4-(2-(benzolsulfonylamino)-ethyl)-phenoxyessigsaeure
CA2061567C (en) * 1992-02-20 1998-02-03 Rudolf E. Falk Use of hyaluronic acid to repair ischemia reperfusion damage
US6462077B1 (en) * 1993-12-28 2002-10-08 Allergan, Inc. Thromboxane ligands without blood clotting side effects
JP4578613B2 (ja) * 2000-04-03 2010-11-10 キヤノンアネルバ株式会社 Ｑポール型質量分析計
US20150174123A1 (en) * 2012-06-29 2015-06-25 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of reperfusion injury
WO2016134257A1 (en) 2015-02-19 2016-08-25 Lixter Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2809377A1 (de) * 1978-03-04 1979-09-13 Boehringer Mannheim Gmbh Phenoxyalkylcarbonsaeure-derivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
DE3000377A1 (de) * 1980-01-07 1981-07-09 Boehringer Mannheim Gmbh, 6800 Mannheim Neue sulfonamide, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
US4537981A (en) * 1981-11-09 1985-08-27 E. R. Squibb & Sons, Inc. 7-Oxabicycloheptane and 7-oxabicycloheptene compounds
US4416896A (en) * 1982-05-17 1983-11-22 E. R. Squibb & Sons, Inc. 7-Oxabicyclopheptane substituted amino prostaglandin analogs useful in the treatment of thrombolytic disease
US4663336A (en) * 1985-07-01 1987-05-05 E. R. Squibb & Sons, Inc. 7-oxabicycloheptane substituted diamide and its congener prostaglandin analogs useful in the treatment of thrombotic disease
US4752616A (en) * 1987-06-29 1988-06-21 E. R. Squibb & Sons, Inc. Arylthioalkylphenyl carboxylic acids, compositions containing same and method of use

Also Published As

Publication number Publication date
JPH0283319A (ja) 1990-03-23
CA1328607C (en) 1994-04-19
EP0309801A2 (de) 1989-04-05
EP0309801B1 (de) 1993-05-12
DE3880943T2 (de) 1993-08-26
EP0309801A3 (en) 1990-07-25
US4931460A (en) 1990-06-05
DE3880943D1 (de) 1993-06-17

Similar Documents

Publication Publication Date Title
DD129788A5 (de) Verfahren zur herstellung von 3',3'',5',5''-tetrachlorphenol-3,4,5,6-tetrabromsulfophthalein bzw.3',3''-dibrom-5',5''-dichlorphenol-3,4,5,6-tetrachlorsulfophthalein
AT373239B (de) Verfahren zur herstellung von neuen 2-hydroxymethyl-3,4,5-trihydroxypiperidinderivaten
DE3885366D1 (de) Verfahren zur Herstellung von Pyrrolo-(3,4-c)pyrrolen.
DE3889393D1 (de) Verfahren zur Herstellung von 2,2,6,6-Tetramethyl-4-piperidylaminen.
ATE18353T1 (de) Verfahren zur herstellung von liposomenloesungen.
DE3854003D1 (de) Verfahren zur Herstellung von N-substituiertem Amin.
DE3866974D1 (de) Verfahren zur herstellung von verbindungen der norbornenstruktur.
DE3862306D1 (de) Verfahren zur elektrochemischen herstellung von carbonsaeuren.
EP0391393A3 (de) Verfahren zur Herstellung von Cefodizim-Dinatrium
DE69016840D1 (de) Verfahren zur Herstellung eines lateralen Bipolartransistors.
DE3861825D1 (de) Verfahren zur herstellung von (2,2)-paracyclophan.
DE58906162D1 (de) Verfahren zur Herstellung eines gegebenenfalls substituierten Chinacridons.
DE3880943D1 (de) Verwendung von thromboxan-a2-antagonisten zur herstellung eines arzneimittels zur wiederherstellung von post-ischaemischer myokard-dysfunktion.
DE68923534D1 (de) Verfahren zur Herstellung eines organischen Kristalls.
AT344168B (de) Verfahren zur herstellung von neuen 1,3-dioxanen bzw. -dioxolanen
DE3882251D1 (de) Verfahren zum herstellen eines bipolaren transistors unter verwendung von cmos-techniken.
DE3881091D1 (de) Verfahren zur herstellung von phosphatidsaeurederivaten.
DE68916760D1 (de) Verfahren zur Herstellung von Gamma-Lactonen.
DE3765956D1 (de) Verfahren zur herstellung von 1-methyl-3,5,7-triaza-1-azoniatricyclodecan-halogeniden.
AT369264B (de) Verfahren zur herstellung von efeuextrakten bzw. von alpha-hederin
DE69007294D1 (de) Verfahren zur herstellung eines aktiven feinen zuschlagstoffes zur betonherstellung.
AT371443B (de) Verfahren zur herstellung von neuen 1-benzyl -1,2,3,6-tetrahydropyridinderivaten
DE3887212D1 (de) Verfahren zur Herstellung von Derivaten von 6,7-Diazyl-7-desacetylforskolin.
AT347422B (de) Verfahren zur herstellung des optisch aktiven (4r,6r)-4-hydroxy-2,2,6-trimethyl-cyclohexanon
ATA63776A (de) Verfahren zur herstellung von 1,2-benzisothiazolen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee